Lyric Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics for gastrointestinal indications. The company in‑licensed its initial development candidate in September 2014. It intends to use new financing to perform two clinical studies, including a clinical proof-of-concept study, and other supportive activities. Lyric was co-founded in 2013 by David Wurtman, M.D., M.B.A. (President & CEO) and M. Scott Harris, M.D. (Chief Medical Officer). The company is based in South San Francisco, California. Prior to the Series A, Lyric closed a $825k seed round in 2014 led by RiverVest Venture Partners.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2015